GlaxoSmithKline (NYSE:GSK) recently announced its intention to commence a tender offer to acquire the outstanding shares of Human Genome Sciences, Inc. (NASDAQ:HGSI) for a cash payment of $13 per share. Glaxo decided that it will not take part in the strategic review being conducted by Human Genome.
We note that the tender offer will remain open for 20 business days after its commencement. According to Glaxo, its offer provides Human Genome shareholders with the option to make their own decision … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here